Service d'immuno-rhumatologie, Lapeyronie Hospital, Montpellier 1 University, Montpellier cedex 5, France.
Joint Bone Spine. 2011 Dec;78(6):587-92. doi: 10.1016/j.jbspin.2011.01.010. Epub 2011 Mar 27.
To describe the means of optimizing methotrexate therapy for rheumatoid arthritis in daily clinical practice, based on a systematic literature review.
We systematically reviewed the literature by searching the PubMed, Embase, and Cochrane databases and reviewing communications to ACR and EULAR meetings for studies on methotrexate starting dosages, dosage increment sizes and intervals, maximum dosages, and routes of administration in patients with rheumatoid arthritis. We used an appropriate scoring system to assess the methodological quality of each selected study.
We identified 519 studies of which 11 were selected based on the titles and abstracts then on the full-length articles. Methotrexate was optimally effective when started in a high dosage (more than 10mg/week orally) that was subsequently increased by 5mg/month up to 25-30mg/week,(1) with appropriate adjustments based on clinical disease activity and tolerance of each patient. For a given methotrexate dosage, parenteral administration was more effective and produced fewer gastrointestinal adverse effects than oral administration.
The information supplied by this systematic review support higher starting dosage, an intensive dosage increase schedule and recourse to parenteral administration in case of unresponsiveness or intolerance to oral methotrexate. They should improve the management of patients given methotrexate therapy for rheumatoid arthritis.
基于系统文献回顾,描述在日常临床实践中优化甲氨蝶呤治疗类风湿关节炎的方法。
我们通过检索 PubMed、Embase 和 Cochrane 数据库,并回顾 ACR 和 EULAR 会议的交流信息,对甲氨蝶呤起始剂量、剂量递增大小和间隔、最大剂量以及类风湿关节炎患者给药途径的研究进行了系统综述。我们使用适当的评分系统评估了每个入选研究的方法学质量。
我们共确定了 519 项研究,其中 11 项研究是基于标题和摘要,然后是全文入选的。甲氨蝶呤以高剂量(每周超过 10mg 口服)起始,随后每月增加 5mg,最高可达 25-30mg/周时,效果最佳,(1)根据每位患者的临床疾病活动度和耐受性进行适当调整。对于给定的甲氨蝶呤剂量,与口服给药相比,静脉给药更有效,且胃肠道不良反应更少。
本系统综述提供的信息支持更高的起始剂量、更密集的剂量递增方案以及在口服甲氨蝶呤无效或不耐受时采用静脉给药。这些信息应该会改善类风湿关节炎患者接受甲氨蝶呤治疗的管理。